Kidney Cancer

Updates from the 2008 annual meeting of the American Society of Clinical Oncology includes news on lung, breast, colorectal, and kidney cancers.

Childhood cancer garners sympathy from all, but drug development from few.

Adult cancers are biologically different from childhood cancer, resulting in different treatments and different success rates.

Researchers explore ways to improve drug evaluations in pediatric clinical trials.

Advocates are working together to increase awareness and research in childhood cancers.

Drug development in childhood cancer has picked up the pace in recent years.

Childhood cancer survivors are at higher risk for heart disease.

Igniting progress in the cure of children with cancer.

Twins' blood may explain how childhood leukemia develops.

Lu Sipos' Chemo Duck comforts childhood cancer patients.

Blood counts predict leukemia survival and relapse.

Senate passes the Conquer Childhood Cancer Act for research funding.

Some cancer therapies can increase the risk of secondary cancers such as sarcoma, especially for childhood cancer survivors.

Delayed diagnosis too common.

The FDA approves third kidney cancer drug and blood-clotting therapy while delaying review on a prostate cancer vaccine, and one drug edges another in a colorectal cancer clinical trial.

Updates from the 2007 meeting of the American Society of Clinical Oncology includes news on liver, kidney, lung, colon, pancreatic and breast cancers.

Genetic nondiscrimination bill on its way to becoming law.

Gamers take virtual shot at cancer.

Statistics on the long-term heart effects of therapy include risk factors that increase the likelihood of heart damage in a childhood cancer survivor.

Cognitive dysfunction remains a problem for young patients.

A documentary film about kids with cancer and their families.

Tips for parents--there are several things parents can do to make their other children feel special and involved in their sibling's cancer battle.

In addition to treatment-related risks, some survivors discover they have a genetic syndrome that may lead to a second cancer.

Updates from the 2006 annual meeting of the American Society of Clinical Oncology.

Revlimid is approved for certain types of myelodysplastic syndrome, and Sutent was approved for both advanced kidney cancer and gastrointestinal stromal tumor.

Advanced treatments take form for a notoriously hard-to-beat cancer.